Dr. Anas Alharbi, an Internal Medicine Resident at West Virginia University, in Morgantown, WV, reviews outcomes of his study appearing in the December 2020 issue of Mayo Clinic Proceedings, that found TAVR - Transcatheter Aortic Valve Replacement - was a safe and viable option for a group of patients with pure aortic insufficiency previously thought not to be candidates for treatment due to age and comorbidities, when compared with a similar patient population treated with SAVR – Surgical Aortic Valve Replacement. He found no difference in mortality outcomes and shorter hospital stays in the TAVR group. Available at: [ Ссылка ]
